Latest news from Thermedical on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/thermedical-announces-fda-approval-of-clinical-trial-for-serf-ablation-to-treat-patients-with-ventricular-tachycardia-leading-cause-of-sudden-cardiac-death/?sc=rsin /articles/thermedical-announces-fda-approval-of-clinical-trial-for-serf-ablation-to-treat-patients-with-ventricular-tachycardia-leading-cause-of-sudden-cardiac-death/?sc=rsin Wed, 24 Aug 2022 11:00:36 EST WALTHAM, Mass., Aug. 23, 2022 - Thermedical(r), a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an open-label, single-arm interventional clinical trial to evaluate the safety and efficacy of the Thermedical(r) SERF Ablation System with the Durablate(r) Catheter in people with ventricular tachycardia (VT) resistant to conventional treatment. Thermedical